Longitudinal analysis of usage and public awareness of tyrosine kinase inhibitors for CML
These data highlight a shift toward newer TKIs in CML treatment, mirroring guideline recommendations and rising public awareness. Online search trends complement traditional prescription monitoring, oCering near real-time insights into evolving prescribing practices and drug adoption.
Authors
- Michael Joseph Blaha (ORCID: https://orcid.org/0000-0001-5138-9683)
- Tiffany Javadi (ORCID: https://orcid.org/0009-0008-4731-0280)
- Joseph R. McFarland
- Akram Sadeghi (ORCID: https://orcid.org/0000-0002-9625-5301)
- Furkan Torlak
- Jamaal L. Benjamin
- Philipp Berning (ORCID: https://orcid.org/0000-0003-0442-3521)
- Omar Dzaye (ORCID: https://orcid.org/0000-0001-9483-3510)
- Ankit Mehta
- Alice Roxo Nobre de Souza e Silva (ORCID: https://orcid.org/0000-0003-3252-3511)
- Girish Kumar
- Philipp le Coutre
- Adrian E. Schroer
- Moaz M. Choudhary
Institutions
- Johns Hopkins University (US)
- Emory University (US)
- Johns Hopkins Medicine (US)
- Humboldt-Universität zu Berlin (DE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.3389/fonc.2025.1711453
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00